This project analyzes the evolving landscape of obesity treatment, examining real-world effectiveness, the growing drug pipeline (including incretins, amylin analogs like cagrilintide and pramlintide, and MC4R agonists), clinical trial trends, the development of holistic treatment approaches targeting metabolic complications, and the impact of diverse healthcare pricing and reimbursement models on access and affordability.
Several medications are in late-stage development or recently approved for obesity treatment, showing varying efficacy and safety profiles:• Incretin-based therapies: This class includes GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide, liraglutide, and newer agents like orforglipron, as well as dual and triple receptor agonists (e.g., tirzepatide, retatrutide).
These medications have shown significant weight loss, ranging from 5% to over 20% of baseline body weight, with higher percentages observed in some newer agents. Common side effects are primarily gastrointestinal, such as nausea, vomiting, and diarrhea.• Other emerging therapies:• Cagrilintide, a long-acting amylin analogue. has shown promise in early trials, especially in combination
Several medications are in late-stage development or recently approved for obesity treatment, showing varying efficacy and safety profiles:• Incretin-based therapies: This class includes GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide, liraglutide, and newer agents like orforglipron, as well as dual and triple receptor agonists (e.g., tirzepatide, retatrutide).
These medications have shown significant weight loss, ranging from 5% to over 20% of baseline body weight, with higher percentages observed in some newer agents. Common side effects are primarily gastrointestinal, such as nausea, vomiting, and diarrhea.• Other emerging therapies:• Cagrilintide, a long-acting amylin analogue. has shown promise in early trials, especially in combination
Several medications are in late-stage development or recently approved for obesity treatment, showing varying efficacy and safety profiles:• Incretin-based therapies: This class includes GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide, liraglutide, and newer agents like orforglipron, as well as dual and triple receptor agonists (e.g., tirzepatide, retatrutide).
These medications have shown significant weight loss, ranging from 5% to over 20% of baseline body weight, with higher percentages observed in some newer agents. Common side effects are primarily gastrointestinal, such as nausea, vomiting, and diarrhea.• Other emerging therapies:• Cagrilintide, a long-acting amylin analogue. has shown promise in early trials, especially in combination